Figure 7.

The most negatively correlated agonist/antagonist miRNA pairs influence patient survival. (A) Correlations and regression analyses between the most negatively correlated agonist/antagonist pairs in primary cancers (all correlations are summarized in Additional file 13: Table S12). Each dot denotes a patient. (B) Expression ratios of the most negatively correlated agonist/antagonist pairs in primary cancers grouped according to the patient survival (< 5 years and > 5 years for OvCa and KIRC; < 3 years and > 3 years for GBM). (C) Kaplan-Meier survival analysis of GBM patients stratified according to the two most negative agonist/antagonist miRNA pairs (left panel, miR-93/miR-221 ratio; right panel, miR-19a/miR-222 ratio). Solid lines, survival of patients with agonist/antagonist miRNA ratios in the bottom half; dashed lines, survival of patients with agonist/antagonist miRNA ratios in the top half.

Hua et al. BMC Genomics 2013 14:179   doi:10.1186/1471-2164-14-179
Download authors' original image